These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 36694943)
1. Blood-brain barrier opening of the default mode network in Alzheimer's disease with magnetic resonance-guided focused ultrasound. Meng Y; Goubran M; Rabin JS; McSweeney M; Ottoy J; Pople CB; Huang Y; Storace A; Ozzoude M; Bethune A; Lam B; Swardfager W; Heyn C; Abrahao A; Davidson B; Hamani C; Aubert I; Zetterberg H; Ashton NJ; Karikari TK; Blennow K; Black SE; Hynynen K; Lipsman N Brain; 2023 Mar; 146(3):865-872. PubMed ID: 36694943 [TBL] [Abstract][Full Text] [Related]
2. Focused ultrasound-mediated blood-brain barrier opening in Alzheimer's disease: long-term safety, imaging, and cognitive outcomes. Rezai AR; Ranjan M; Haut MW; Carpenter J; D'Haese PF; Mehta RI; Najib U; Wang P; Claassen DO; Chazen JL; Krishna V; Deib G; Zibly Z; Hodder SL; Wilhelmsen KC; Finomore V; Konrad PE; Kaplitt M; J Neurosurg; 2023 Jul; 139(1):275-283. PubMed ID: 36334289 [TBL] [Abstract][Full Text] [Related]
3. Transcranial blood-brain barrier opening in Alzheimer's disease patients using a portable focused ultrasound system with real-time 2-D cavitation mapping. Bae S; Liu K; Pouliopoulos AN; Ji R; Jiménez-Gambín S; Yousefian O; Kline-Schoder AR; Batts AJ; Tsitsos FN; Kokossis D; Mintz A; Honig LS; Konofagou EE Theranostics; 2024; 14(11):4519-4535. PubMed ID: 39113808 [No Abstract] [Full Text] [Related]
4. Evaluation of tau deposition using Bullich S; Mueller A; De Santi S; Koglin N; Krause S; Kaplow J; Kanekiyo M; Roé-Vellvé N; Perrotin A; Jovalekic A; Scott D; Gee M; Stephens A; Irizarry M Alzheimers Res Ther; 2022 Jul; 14(1):105. PubMed ID: 35897078 [TBL] [Abstract][Full Text] [Related]
5. APOE4 leads to blood-brain barrier dysfunction predicting cognitive decline. Montagne A; Nation DA; Sagare AP; Barisano G; Sweeney MD; Chakhoyan A; Pachicano M; Joe E; Nelson AR; D'Orazio LM; Buennagel DP; Harrington MG; Benzinger TLS; Fagan AM; Ringman JM; Schneider LS; Morris JC; Reiman EM; Caselli RJ; Chui HC; Tcw J; Chen Y; Pa J; Conti PS; Law M; Toga AW; Zlokovic BV Nature; 2020 May; 581(7806):71-76. PubMed ID: 32376954 [TBL] [Abstract][Full Text] [Related]
6. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy. Tateno A; Sakayori T; Kawashima Y; Higuchi M; Suhara T; Mizumura S; Mintun MA; Skovronsky DM; Honjo K; Ishihara K; Kumita S; Suzuki H; Okubo Y Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833 [TBL] [Abstract][Full Text] [Related]
7. Pilot study of repeated blood-brain barrier disruption in patients with mild Alzheimer's disease with an implantable ultrasound device. Epelbaum S; Burgos N; Canney M; Matthews D; Houot M; Santin MD; Desseaux C; Bouchoux G; Stroer S; Martin C; Habert MO; Levy M; Bah A; Martin K; Delatour B; Riche M; Dubois B; Belin L; Carpentier A Alzheimers Res Ther; 2022 Mar; 14(1):40. PubMed ID: 35260178 [TBL] [Abstract][Full Text] [Related]
8. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum. Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M; Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949 [TBL] [Abstract][Full Text] [Related]
9. Network Disruption and Cerebrospinal Fluid Amyloid-Beta and Phospho-Tau Levels in Mild Cognitive Impairment. Canuet L; Pusil S; López ME; Bajo R; Pineda-Pardo JÁ; Cuesta P; Gálvez G; Gaztelu JM; Lourido D; García-Ribas G; Maestú F J Neurosci; 2015 Jul; 35(28):10325-30. PubMed ID: 26180207 [TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier opening in Alzheimer's disease using MR-guided focused ultrasound. Lipsman N; Meng Y; Bethune AJ; Huang Y; Lam B; Masellis M; Herrmann N; Heyn C; Aubert I; Boutet A; Smith GS; Hynynen K; Black SE Nat Commun; 2018 Jul; 9(1):2336. PubMed ID: 30046032 [TBL] [Abstract][Full Text] [Related]
11. Cortical hypometabolism reflects local atrophy and tau pathology in symptomatic Alzheimer's disease. Strom A; Iaccarino L; Edwards L; Lesman-Segev OH; Soleimani-Meigooni DN; Pham J; Baker SL; Landau SM; Jagust WJ; Miller BL; Rosen HJ; Gorno-Tempini ML; Rabinovici GD; La Joie R; Brain; 2022 Apr; 145(2):713-728. PubMed ID: 34373896 [TBL] [Abstract][Full Text] [Related]
12. Plasma Core Alzheimer's Disease Biomarkers Predict Amyloid Deposition Burden by Positron Emission Tomography in Chinese Individuals with Cognitive Decline. Ni M; Zhu ZH; Gao F; Dai LB; Lv XY; Wang Q; Zhu XX; Xie JK; Shen Y; Wang SC; Xie Q; ACS Chem Neurosci; 2023 Jan; 14(1):170-179. PubMed ID: 36547971 [TBL] [Abstract][Full Text] [Related]
13. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort. Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669 [TBL] [Abstract][Full Text] [Related]
15. Tau-PET abnormality as a biomarker for Alzheimer's disease staging and early detection: a topological perspective. Ding J; Shen C; Wang Z; Yang Y; El Fakhri G; Lu J; Liang D; Zheng H; Zhou Y; Sun T; Cereb Cortex; 2023 Oct; 33(20):10649-10659. PubMed ID: 37653600 [TBL] [Abstract][Full Text] [Related]
16. A phase II study repurposing atomoxetine for neuroprotection in mild cognitive impairment. Levey AI; Qiu D; Zhao L; Hu WT; Duong DM; Higginbotham L; Dammer EB; Seyfried NT; Wingo TS; Hales CM; Gámez Tansey M; Goldstein DS; Abrol A; Calhoun VD; Goldstein FC; Hajjar I; Fagan AM; Galasko D; Edland SD; Hanfelt J; Lah JJ; Weinshenker D Brain; 2022 Jun; 145(6):1924-1938. PubMed ID: 34919634 [TBL] [Abstract][Full Text] [Related]
17. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related]
18. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900 [TBL] [Abstract][Full Text] [Related]
19. Cerebrospinal-fluid Alzheimer's Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinson's Disease Patients. Liguori C; Olivola E; Pierantozzi M; Cerroni R; Galati S; Saviozzi V; Mercuri NB; Stefani A CNS Neurol Disord Drug Targets; 2017; 16(3):339-345. PubMed ID: 27934563 [TBL] [Abstract][Full Text] [Related]
20. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition. Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA; Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]